Venable Fitzpatrick partner Ha Kung Wong spoke at ISPOR’s annual conference as part of a panel that discussed the biosimilar market in the US. As a follow-up to that presentation, Ha Kung participated in a Q&A for Biosimilar Development, including providing thoughts on:
- What we have learned from the biosimilar experience in Europe and implications for biosimilar hurdles in the U.S.
- The greatest market access hurdles/challenges to overcome in the biosimilars field within the U.S. market and what could be done to address these challenges
- Key areas for improvement within the biosimilar industry
The article can be viewed here.